Influence of chitosan glutamate on the in vivo intranasal absorption of rokitamycin from microspheres

Journal of Pharmaceutical Sciences

Volumn 100, Issue 4, 2011, Pages 1488-1502

  Gavini, Elisabetta ^a   Rassu, Giovanna ^a   Ferraro, Luca ^b   Generosi, Amanda ^c   Rau, Julietta V ^c   Brunetti, Antonio ^a   Giunchedi, Paolo ^a   Dalpiaz, Alessandro ^b  

^a UNIVERSITY OF SASSARI   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c CNR   (Italy)

Author keywords

Brain targeting; Chitosan; CNS; Controlled release delivery; In vivo studies; Microspheres; Nasal drug delivery; Rokitamycin; Site specific delivery; Spray drying

Indexed keywords

CHITOSAN; GLUTAMIC ACID; MICROSPHERE; ROKITAMYCIN; ANTIINFECTIVE AGENT; DELAYED RELEASE FORMULATION; MIOKAMYCIN;

ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; DISSOLUTION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; MUCOADHESION; NONHUMAN; PARTICLE SIZE; RAT; SPRAY DRYING; WATER TRANSPORT; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DELAYED RELEASE FORMULATION; INTRANASAL DRUG ADMINISTRATION; WISTAR RAT;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTI-BACTERIAL AGENTS; CHITOSAN; DELAYED-ACTION PREPARATIONS; GLUTAMIC ACID; HUMANS; MALE; MICROSPHERES; MIOCAMYCIN; NASAL ABSORPTION; RATS; RATS, WISTAR;

EID: 79951885109     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22382     Document Type: Article

References (89)

1. Sinha VR, Singla AK, Wadhawan S, Kaushik R, Kumria R, Bansal K, Dhawan S. 2004. Chitosan microspheres as a potential carrier for drugs. Int J Pharm 274:1-33.
2. Singla AK, Chawla M. 2001. Chitosan: Some pharmaceutical and biological aspects-an update. J Pharm Pharmacol 53:1047-1067.
3. Maestrelli F, Zerrouk N, Chemtob C, Mura P. 2004. Influence of chitosan and its glutamate and hydrochloride salts on naproxen dissolution rate and permeation across Caco-2 cells. Int J Pharm 271:257-267.
4. Corti G, Maestrelli F, Cirri M, Mura P, Zerrouk N. 2008. Dissolution and permeation properties of naproxen from solid-state systems with chitosan. Drug Deliv 15:303-312.
5. Rossi S, Marciello M, Sandri G, Bonferoni MC, Ferrari F, Caramella C. 2008. Chitosan ascorbate: A chitosan salt with improved penetration enhancement properties. Pharm Dev Technol 13:513-521.
6. Di Colo G, Zambito Y, Burgalassi S, Nardini I, Saettone MF. 2004. Effect of chitosan and of N-carboxymethylchitosan on intraocular penetration of topically supplied ofloxacin. Int J Pharm 273:37-44.
7. Van der Merwe SM, Verhoef JC, Verheijden JH, Kotzé AF, Junginger HE. 2004. Trimethylated chitosan as polymeric absorption enhancer for improved peroral delivery of peptide drugs. Eur J Pharm Biopharm 58:225-235.
8. Zambito Y, Zaino C, Di Colo G. 2006. Effect of N-trimethylchitosan on transcellular and paracellular transcorneal drug transport. Eur J Pharm Biopharm 64:16-25.
9. Thanou M, Verhoef JC, Junginger HE. 2001. Chitosan and its derivatives as intestinal absorption enhancers. Adv Drug Deliv Rev 50:S91-S101.
10. Sandri G, Rossi S, Ferrari F, Bonferoni MC, Muzzarelli C, Caramella C. 2004. Assessment of chitosan derivatives as buccal and vaginal penetration enhancers. Eur J Pharm Sci 21:351-359.
11. Ravi Kumar MNV, Muzzarelli RAA, Muzzarelli C, Sashiwa H, Domb AJ. 2004. Chitosan chemistry and pharmaceutical perspectives. Chem Rev 104:6017-6084.
12. Rassu G, Gavini E, Jonassen H, Zambito Y, Fogli S, Breschi MC, Giunchedi P. 2009. New chitosan derivatives for the preparation of rokitamycin loaded microspheres designed for ocular or nasal administration. J Pharm Sci 98:4852-4865.
13. Gavini E, Rassu G, Muzzarelli C, Cossu M, Giunchedi P. 2008. Spray-dried microspheres based on methylpyrrolidinone chitosan as new carrier for nasal administration of metoclopramide. Eur J Pharm Biopharm 68:245-252.
14. Gavini E, Rassu G, Haukvik T, Lanni C, Racchi M, Giunchedi P. 2009. Mucoadhesive microspheres for nasal administration of cyclodextrins. J Drug Target 17:168-179.
15. Mei D, Mao S, Sun W, Wang Y, Kissel T. 2008. Effect of chitosan structure properties and molecular weight on the intranasal absorption of tetramethylpyrazine phosphate in rats. Eur J Pharm Biopharm 70:874-881.
16. Alpar HO, Somavarapu S, Atuah KN, Bramwell VW. 2005. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv Drug Deliv Rev 57:411-430.
17. Illum L. 2004. Is nose-to-brain transport of drugs in man a reality?. J Pharm Pharmacol 56:3-17.
18. Thorne RG, Frey WH. 2001. Delivery of neurotropic factors to the central nervous system. Clin Pharmacokinet 40:907-946.
19. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH. 2004. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127:481-496.
20. Seki T, Sato N, Hasegawa T, Kawaguchi T, Juni K. 1994. Nasal adsorption of zidovudine and its transport to cerebrospinal fluid in rats. Biol Pharm Bull 17:1135-1137.
21. Chou KJ, Donovan MD. 1998. The distribution of local anesthetics into the CSF following intranasal administration. Int J Pharm 168:137-145.
22. Chou KJ, Donovan MD. 1998. Lidocaine distribution into the CNS following nasal and arterial delivery: A comparison of local sampling and microdialysis techniques. Int J Pharm 171:53-61.
23. Chou KJ, Donovan MD. 1997. Distribution of antihistamines into the CSF following the intranasal delivery. Biopharm Drug Disp 18:335-346.
24. Kandimalla KK, Donovan MD. 2005. Transport of hydroxyzine and tripolidine across bovine olfactory mucosa: Role of passive diffusion in the direct nose-to-brain uptake of small molecules. Int J Pharm 302:133-144.
25. Dahlin M, Jansson B, Bjork E. 2001. Levels of dopamine in blood and brain following nasal administration to rats. Eur J Pharm Sci 14:75-80.
26. Kubek MJ, Domb AJ, Veronesi MC. 2009. Attenuation of kindled seizures by intranasal delivery of neuropeptide-loaded nanoparticles. Neurotherapeutics 6:359-371.
27. Frey II WH. 1997. Method of administering neurologic agents to the brain. Patent US 5624898. Chiron Corporation.
28. Capsoni S, Giannotta S, Cattaneo A. 2002. Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc Natl Acad Sci USA 99:12432-12437.
29. De Rosa R, Garcia AA, Braschi C, Capsoni S, Maffei L, Berardi N, Cattaneo A. 2005. Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti- NGF transgenic mice. Proc Natl Acad Sci USA 102:3811-3816.
30. Hashizume R, Ozawa T, Gryaznov SM, Bollen AW, Lamborn KR, Frey II WH, Deen DF. 2008. New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163. Neuro Oncol 10:112-120.
31. Hanson LR, Frey II WH. 2007. Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuroAIDS. J Neuroimmune Pharmacol 2:81-86.
32. Liu XF, Fawcett JR, Thorne RG, Frey II WH. 2001. Non-invasive intranasal insulin-like growth factor-I reduces infarct volume and improves neurologic function in rats following middle cerebral artery occlusion. Neurosci Lett 308:91-94.
33. Wei G, Wang D, Lu H, Parmentier S, Wang Q, Panter S, Frey II WH. 2007. Intranasal administration of a PARG inhibitor profoundly decreases ischemic brain injury. Front Biosci 12:4986-4996.
34. Dhuria SV, Hanson LR, Frey II WH. 2010. Intranasal delivery to the central nervous system: Mechanisms and experimental considerations. J Pharm Sci 99:1654-1673.
35. Frey WH II. 2001. Method for administering insulin to the brain. Patent US 6313093. Chiron Corporation.
36. Reger MA, Watson GS, Frey II WH, Baker LD, Cholerton B, Keeling ML, Belongia DA, Fishel MA, Plymate SR, Schellenberg GD, Cherrier MM, Craft S. 2006. Effects of intranasal insulin on cognition in memory-impaired older adults: Modulation by APOE genotype. Neurobiol Aging 27:451-458.
37. Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JC, DeGroodt W, Mehta P, Craft S. 2008. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 70:440-448.
38. Benedict C, Hallschmid M, Hatke A, Schultes B, Fehm HL, Born J, Kern W. 2004. Intranasal insulin improves memory in humans. Psychoneuroendocrinology 29:1326-1334.
39. Benedict C, Hallschmid M, Schmitz K, Schultes B, Ratter F, Fehm HL, Born J, Kern W. 2007. Intranasal insulin improves memory in humans: Superiority of insulin aspart. Neuropsychopharmacology 32:239-243.
40. Danielyan L, Schäfer R, von Ameln-Mayerhofer A, Buadze M, Geisler J, Klopfer T, Burkhardt U, Proksch B, Verleysdonk S, Ayturan M, Buniatian GH, Gleiter CH, Frey II WH. 2009. Intranasal delivery of cells to the brain. Eur J Cell Biol 88:315-324.
41. Dhuria SV, Hanson LR, Frey II WH. 2009. Novel vasoconstrictor formulation to enhance intranasal targeting of neuropeptide therapeutics to the central nervous system. J Pharmacol Exp Ther 328:312-320.
42. Patel MM, Goyal BR, Bhadada SV, Bhatt JS, Amin AF. 2009. Getting into the brain: Approaches to enhance brain drug delivery. CNS Drugs 23:35-58.
43. Dalpiaz A, Gavini E, Colombo G, Russo P, Bortolotti F, Ferraro L, Tanganelli S, Scatturin A, Menegatti E, Giunchedi P. 2008. Brain uptake of an antiischemic agent by nasal administration of microparticles. J Pharm Sci 97:4889-4903.
44. Kanfer I, Skinner MF, Walker RB. 1998. Analysis of macrolide antibiotics. J Chromatogr A 812:255-286.
45. Mazzariol A, Koncan R, Vitali LA, Cornaglia G. 2007. Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant streptococcus pyogenes and streptococcus pneumonia. J Antimicrob Chemother 59:1171-1176.
46. Yano H, Kobayashi T, Okitsu N, Aoki A, Toriya M, Nakada Y, Sagai H, Iyobe S, Inoue M. 2007. Comparison of antimicrobial and bactericidal activities and postantibiotic effects of macrolides antibiotics against clinical isolates, and examination of shape alteration by scanning electron microscope. Jpn J Antibiot 60:31-46.
47. Schuster FL, Visvesvara GS. 2004. Free-living amoebae as opportunistic and non-opportunistic pathogens of humans and animals. Int J Parasitol 34:1001-1027.
48. Jeansson S, Kvien TK. 2001. Acanthamoeba polyphaga in rheumatoid arthritis: Possibility for a chronic infection. Scand J Immunol 53:610-614.
49. Levine S, Goldstein AE, Dahdouh M, Blank P, Hoffman C, Gropper CA. 2001. Cutaneous Acanthamoeba in a patient with AIDS: A case study with a review of new therapy. Cutis 67:377-380.
50. Torno MS, Babapour R, Gurevitch A, Witt MD. 2000. Cutaneous acanthamoebiasis in AIDS. J Am Acad Dermatol 42:351-354.
51. Khan NA. 2008. Acanthamoeba and the blood-brain barrier: The breakthrough. J Med Microbiol 57:1051-1057.
52. Mattana A, Biancu G, Alberti L, Accardo A, Delogu G, Fiori PL, Cappuccinelli P. 2004. In vitro evaluation of the effectiveness of the macrolide rokitamycin and chlorpromazine against Acanthamoeba castellanii. Antimicrob Agents Chemother 48:4520-4527.
53. Rassu G, Gavini E, Mattana A, Giunchedi P. 2008. Improvement of antiamoebic activity of rokitamycin loaded in chitosan microspheres. Open Drug Del J 2:38-43.
54. Gavini E, Rassu G, Sanna V, Cossu M, Giunchedi P. 2005. Mucoadhesive microspheres for nasal administration of an antiemetic drug, metoclopramide: In-vitro/ex-vivo studies. J Pharm Pharmacol 57:287-294.
55. Cullity BD, Stock SR. 2001. Elements of X-ray diffraction. 2nd ed. New Jersey: Addison-Wesley publishing Company Inc, Prentice Hall.
56. Caminiti R, Rossi Albertini V. 1999. The kinetics of phase transitions observed by energy-dispersive X-ray diffraction. Int Rev Phys Chem B 18:263-269.
57. Sacchetti C, Artusi M, Santi P, Colombo P. 2002. Caffeine microparticles for nasal administration obtained by spray drying. Int J Pharm 242:335-339.
58. Tod M, Biarez O, Nicolas P, Petitjean O. 1992. Sensitive determination of josamycin and rokitamycin in plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 575:171-176.
59. Ferraro L, Tomasini MC, Fernandez M, Bebe BW, O'Connor WT, Fuxe K, Glennon JC, Tanganelli S, Antonelli T. 2001. Nigral neurotensin receptor regulation of nigral glutamate and nigroventral thalamic GABA transmission: A dual-probe microdialysis study in intact conscious rat brain. Neuroscience 102:113-120.
60. Giunchedi P, Conte U. 1995. Spray-drying as a preparation method of microparticulate drug delivery systems: An overview. STP Pharm Sci 5:276-290.
61. Chan H-K, Chew NYK. 2003. Novel alternative methods for the delivery of drugs for the treatment of asthma. Adv Drug Deliv Rev 55:793-805.
62. Rassu G, Gavini E, Marceddu S, Spada G, Giunchedi P. 2008. Ketoprofen spray-dried microspheres based on Eudragit® RS and RL: Study of the manufacturing parameters. Drug Dev Ind Pharm 34:1178-1187.
63. Patterson AL. 1939. The Scherrer formula for X-ray particle size determination. Phys Rev 56:978-982.
64. Frey II WH. 2002. Bypassing the blood-brain barrier to delivery therapeutic agents to the brain and spinal cord. Drug Del Tech 2:46-49.
65. Dhanda DS, Frey II WH, Leopold D, Kompella UB. 2005. Approaches for drug deposition in the human olfactory epithelium. Drug Del Tech 5:64-72.
66. Costantino HR, Illum L, Brandt G, Johnson PH, Quay SC. 2007. Intranasal delivery: Physicochemical and therapeutic aspects international. Int J Pharm 337:1-24.
67. llum L. 2000. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 11:1-18.
68. Vyas TK, Shahiwala A, Marathe S, Misra A. 2005. Intranasal drug delivery for brain targeting. Curr Drug Deliv 2:165-175.
69. Kumar M, Misra A, Babbar AK, Mishra AK, Mishra P, Pathak K. 2008. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int J Pharm 358:285-291.
70. Junginger HE, Verhoef JC. 1998. Macromolecules as safe penetration enhancers for hydrophilic drugs-a fiction?. Pharm Sci Technol Today 1:370-376.
71. Yu S, Zhao Y, Wu F, Zhang X, Lü W, Zhang H, Zhang Q. 2004. Nasal insulin delivery in the chitosan solution: In vitro and in vivo studies. Int J Pharm 281:11-23.
72. Charlton ST, Davis SS, Illum L. 2007. Nasal administration of an angiotensin antagonist in the rat model: Effect of bioadhesive formulations on the distribution of drugs to the systemic and central nervous systems. Int J Pharm 338:94-103.
73. Petitjean O, Tod M, Louchahi K. 1995. Influence of methodological aspects on tissue drug concentration estimation. J Pharm Biomed Anal 13:817-822.
74. Portero A, Remunan-Lopez C, Vila-Jato JL. 1998. Effect of chitosan and chitosan glutamate enhancing the dissolution properties of the poorly water soluble drug nifedipine. Int J Pharm 175:75-84.
75. Mura P, Zerrouk N, Mennini N, Maestrelli F, Chemtob C. 2003. Development and characterization of naproxen-chitosan solid systems with improved drug dissolution properties. Eur J Pharm Sci 19:67-75.
76. Denkbas EB. 2006. Perspectives on: Chitosan drug delivery systems based on their geometries. J Bioact Compat Polym 21:351-368.
77. Gavini E, Hegge AB, Rassu G, Sanna V, Testa C, Pirisino G, Karlsen J, Giunchedi P. 2006. Nasal administration of carbamazepine using chitosan microspheres: In vitro/in vivo studies. Int J Pharm 307:9-15.
78. Ugwoke MI, Agu RU, Verbeke N, Kinget R. 2005. Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives. Adv Drug Deliv Rev 57:1640-1665.
79. Mortazavi SA, Smart JD. 1993. An investigation into the role of water movement and mucus gel dehydration in mucoadhesion. J Control Release 25:197-203.
80. Fransén N, Björk E, Edsman K. 2008. Changes in the mucoadhesion of powder formulations after drug application investigated with a simplified method. J Pharm Sci 97:3855-3864.
81. Hancock BC, Parks M. 2000. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res 17:397-404.
82. Lim ST, Forbes B, Berry DJ, Martin GP, Brown MB. 2002. In vivo evaluation of novel hyaluronan/chitosan microparticulate delivery systems for the nasal delivery of gentamicin in rabbits. Int J Pharm 231:73-82.
83. van der Lubben IM, Verhoef JC, Borchard G, Junginger HE. 2001. Chitosan for mucosal vaccination. Adv Drug Deliv Rev 52:139-144.
84. Baudner BC, Verhoef JC, Giuliani MM, Peppoloni S, Rappuoli R, Del Giudice G, Junginger HE. 2005. Protective immune responses to meningococcal C conjugate vaccine after intranasal immunization of mice with the LTK63 mutant plus chitosan or trimethyl chitosan chloride as novel delivery platform. J Drug Target 13:489-498.
85. Davis SS. 2006. The use of soluble polymers and polymer microparticles to provide improved vaccine responses after parenteral and mucosal delivery. Vaccine 24:S2-S7.
86. Kaur P, Kim K. 2008. Pharmacokinetics and brain uptake of diazepam after intravenous and intranasal administration in rats and rabbits. Int J Pharm 364:27-35.
87. Pavan B, Dalpiaz A, Ciliberti N, Biondi C, Manfredini S, Vertuani S. 2008. Progress in drug delivery to the central nervous system by the prodrug approach. Molecules 13:1035-1065.
88. Yu H, Kim K. 2009. Direct nose-to-brain transfer of a growth hormone releasing neuropeptide hexarelin after intranasal administration to rabbits. Int J Pharm 378:73-79.
89. Illum L. 2003. Nasal drug delivery-possibilities, problems and solutions. J Control Release 87:187-198.